
Gilead Expands Access to Investigational Obeldesivir Through Voluntary Licensing for Ebola Treatment
Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing Gilead Sciences, Inc. announced that it has signed royalty-free voluntary licensing agreements with three generic manufacturers to support potential future access to its investigational antiviral obeldesivir…














